Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial

Written by Customer Service on June 14, 2020. Posted in Public Companies.

Bagsværd, Denmark, 15 June 2020 – Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the trial, adults with type 2 diabetes randomised to once-weekly insulin icodec achieved similar blood sugar control and a similar safety profile compared with adults with type 2 diabetes randomised to once-daily insulin glargine U100. Results were presented during the 80th Scientific Sessions of the American Diabetes Association.1This 26-week, randomised, double-blind, double-dummy, treat-to-target phase 2 clinical trial involved 247 insulin-naïve adults with type 2 diabetes inadequately controlled with metformin with or without a DPP-4i. The primary endpoint showed that the change from baseline to week 26 in blood sugar control (HbA1c) was similar in participants...

Pilgrim’s CEO on Paid Leave of Absence

Written by Customer Service on June 14, 2020. Posted in Public Companies.

GREELEY, Colo., June 14, 2020 (GLOBE NEWSWIRE) — Pilgrim’s Pride Corporation (NASDAQ: PPC) today announced that president and CEO Jayson Penn has begun a paid leave of absence, effective immediately. During his leave of absence, Mr. Penn intends to focus on his defense of the recently disclosed indictment against him, to which he has pleaded not guilty. The Pilgrim’s Board of Directors has appointed Fabio Sandri, Pilgrim’s CFO, as interim president and CEO.“Pilgrim’s operates with the highest standards of integrity and is committed to free and open competition that benefits both customers and consumers,” said Gilberto Tomazoni, chairman of Pilgrim’s Board of Directors. “The board takes the recent allegations very seriously and believes it is in the best interests of both Jayson and the company that he is given the opportunity to...

Stockwik presenterar informationsmemorandum för fullt garanterad företrädesemission om ca 12,5 MSEK

Written by Customer Service on June 14, 2020. Posted in Public Companies.

Informationen i detta pressmeddelande är inte avsedd att publiceras, offentliggöras, eller distribueras, direkt eller indirekt, i eller till, Australien, Hongkong, Kanada, Nya Zeeland, Japan, Schweiz, Singapore, Sydafrika, USA, eller någon annan jurisdiktion där sådan publicering eller distribution skulle bryta mot tillämpliga lagar eller regler. Se avsnittet ”Viktig information” i slutet av detta pressmeddelande.Stockwik Förvaltning AB (publ) publicerar informationsmemorandum för fullt garanterad företrädesemission om 12,48 MSEK samt övertilldelningsemission om 1,87 MSEK i enlighet med beslut vid extra bolagsstämma den 3 juni 2020 i syfte att finansiera förvärv av Admit Ekonomi AB. Informationsmemorandumet finns publicerat i sin helhet på Stockwiks hemsida; www.stockwik.se, på Consensus Asset Managements hemsida; www.consensusam.se/stockwik,...

Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association

Written by Customer Service on June 14, 2020. Posted in Public Companies.

Press release – No. 09 / 2020 Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association The dasiglucagon HypoPal® rescue pen is under FDA review as a potential fast and effective treatment of severe hypoglycemia in diabetes In Phase 3 trials in pediatric and adult patients with diabetes, dasiglucagon has consistently demonstrated a median time to recovery from hypoglycemia of 10 minutesCopenhagen, June 14, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines, presented elaborated results from two Phase 3 clinical studies with dasiglucagon as treatment for severe hypoglycemia as well as one preclinical PK/PD study investigating aqueous...

Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions

Written by Customer Service on June 14, 2020. Posted in Public Companies.

ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American Diabetes Association 80th Scientific Sessions. According to the American Diabetes Association (ADA) guidelines, elevated LDL cholesterol is a common problem for people with diabetes. Also referred to as hyperlipidemia, this condition greatly increases the risk of developing cardiovascular disease.The presentation, titled “Efficacy and Safety of Bempedoic acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data From 4 Phase 3 Clinical Trials” was delivered by Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA Director of the Lipid Clinic at St. Michael’s Hospital and Professor of Medicine and Nutritional...

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Day: June 14, 2020